This review provides a comprehensive list of in vivo and in vitro studies that have investigated alcohol induced dose dumping (AIDD) in modified release dosage forms. Of the numerous classes of drugs commercially available as modified release products, opioids, centrally acting drugs, and drugs with a narrow therapeutic index present high risks from dose dumping, despite being formulated in a manner that releases drug in a tailored or delayed fashion. Awareness of AIDD has led to the withdrawal of a few marketed products by Regulatory Agencies, and black box warnings on others. Since then, significant effort has focused on proving the robustness of a formulation when co-ingested with alcohol. Patient risk is deemed to be low if the formulation and its performance is unimpaired by the presence of 0-40% alcohol under in vivo and in vitro conditions.
Background
In comparison to an immediate release (IR) dosage form, administration of a drug as an oral controlled release (CR), modified release (MR) or extended release (ER) product is a popular approach to ensuring convenience of dosing and sustained therapeutic blood levels over a prolonged time interval (12-24 h). Thus, errors in dosing compliance by the patient or breakthrough pain in the case of pain medications commonly observed with multiple daily dosing (i.e. every 4-6 h) of an IR dosage form, can be easily mitigated by ingestion of a single tablet or capsule formulated as a CR, MR or ER product (henceforth abbreviated as 'MR dosage forms') (Smith et al. 2010) . These advantages have led to a large number of drugs being formulated and marketed as MR dosage forms. In contrast to an IR tablet or capsule, MR dosage forms contain larger amounts of active pharmaceutical ingredient and different excipients that allow the drug to be released in a slow modulated fashion.
A major risk of a MR dosage form is its potential to release the drug rapidly. As an example, several studies note that MR preparations of theophylline show higher serum levels in the fed state (food induced change) (Hendeles et al. 1985; Hendeles et al. 1984; Steffensen & Pedersen 1986; Karim et al. 1985a, b) . Such rapid drug release from a MR dosage form, i.e. dose dumping, results in the administration of a single bolus dose leading to increased exposure levels, possible safety issues and adverse events. This situation is of most concern with drugs that have a narrow therapeutic index or centrally acting drugs, and will impact clinical efficacy. As a result, CDER (Center for Drug Evaluation and Research) published a guidance document on the design of clinical studies to assess the effects of food on the rate and extent of absorption of a drug under fed and fasted conditions (CDER/FDA 2002) .
For this reason, MR dosage forms are designed in a manner such that drug release is well controlled. One way to accomplished this is by entrapping the drug in a matrix that contains a suitable hydrophobic and/or a hydrophilic polymer that regulates drug release and prevents dose dumping. Potential food-induced changes to release rates are determined at the clinical stage by conducting in vivo food effect studies. More commonly, MR dosage forms undergo analytical testing to ensure batchto-batch uniformity of content as well as meet defined in vitro dissolution specifications that provide assurance of the drug being released in its' intended fashion. Thus we note that changes in release rates of MR dosage forms have also been observed with food, but the focus of this paper is with alcohol.
Over the years, several types of drugs have been formulated as MR dosage forms, including drugs with a narrow therapeutic index like theophylline used in the treatment of respiratory disorders (Walden et al. 2007 ). Additionally opioids (e.g. morphine, hydromorphone, oxycodone, dihydrocodeine, and tramadol) used to treat moderate to severe pain associated with cancer are frequently formulated into MR dosage forms (Barkin et al. 2009 ). These drugs have a short half-life in vivo, thus making them excellent candidates for delivery via MR dosage forms where therapy is required for more than a few days. Depending on the type of the drug incorporated into a MR dosage form and the type of excipients or technology used, drug release can be tailored to modify in vivo absorption, as well as pharmacokinetic and pharmacodynamic properties.
Despite being designed to modulate drug release, dose dumping from MR dosage forms containing opioid drugs has become an area of particular concern for regulators. In 2005, Palladone XL™ (hydromorphone hydrochloride), was withdrawn from the market due to a clinical finding that concomitant ingestion of ethanol (alcohol) resulted in a blood levels 6 times higher than those who ingested Palladone XL™ with water (FDA 2005a) . Alcohol causes a disruption in the drug release mechanism leading to the entire dose being released at once due to ingestion of ethanol (Johnson et al. 2007 ). Thus, alcohol induced dose dumping (AIDD) can be defined as the rapid unintended release of a large amount of drug from a MR dosage form resulting from an accidental misuse or from intentional abuse of alcohol with the drug. Co-consumption with alcohol can complicate matters because it may influence the absorption, metabolism and excretion of drugs (Makin & Williams 2000; Weathermon & Crabb 1999) .
The effect of alcohol (ethanol) in intensifying the pharmacodynamic effects of opioids on the central nervous system (CNS) is well known. In addition to its' clinical effects, studies have demonstrated that moderate consumption of ethanol may pose a risk of drug-drug interactions (Weathermon & Crabb 1999; Messiha & Barnes 1979; Linnoila et al. 1979; Palva et al. 1979) . Indeed, though the co-ingestion of alcohol is contraindicated on the label, there is a clinical concern that alcohol may be ingested when a patient is on opioids or other centrally acting pain medications (for example, concomitant ingestion of alcohol with Palladone XL™). Thus, the potential for adverse interactions is enhanced, given the combined clinical effects of alcohol and the drug (Weathermon & Crabb 1999) . Such a scenario would lead to an elevation of side effects like drowsiness or sedation, and depressed respiratory function. Therefore, it is little surprise that the danger of concomitant consumption of alcohol with opioid like pain medication has become a safety concern and attracted attention from regulatory agencies. The relevance here is that the combined pharmacodynamic effect of alcohol and opioids may be even more enhanced by AIDD.
Though prescribing information labels for opioids contain the standard warning that the drug should not be ingested with alcohol, the widespread consumption of alcohol increases this risk. Such findings have been noted in a report by Bernstein et al who highlighted that nearly 42% of 8774 fatalities recorded in New York City, were caused by an accidental overdose of opioids or opioids and other drugs of abuse with co-ingestion of ethanol (Bernstein et al. 2007 ). In fact, in countries like the United States where routine consumption of alcoholic beverages is the norm (Serdula et al. 2004) , it is no surprise that in another publication, the Drug Abuse Warning Network (DAWN) reported that concomitant use of drugs and alcohol accounted for 14% of drugrelated emergency department visits in 2012 ((2012) The DAWN Report: highlights of the 2010 Drug Abuse Warning Network (DAWN) findings on drug-related emergency department visits, in: (SAMSHA) Center for Behavioral Health Statistics and Quality, Rockville, MD.). Given that opioids exhibit enhanced solubility in ethanolic solutions, and that some MR dosage forms contain excipients that rapidly dissolve in ethanol, the potential for dose dumping is intensified.
Since the findings with Palladone XL™, a few other MR dosage forms have undergone a prescribing information label change to include drug-alcohol interactions. In an in vitro study with Avinza® (morphine sulfate extended release capsules), dose dumping was observed when Avinza® (30 mg) was mixed with 900 mL of buffer solutions containing either 20 or 40% ethanol (Avinza Package Insert, Ligand Pharmaceuticals Inc, San Diego, CA). Not surprisingly, the amount and rate of drug release was faster at higher alcohol concentrations. Though an in vivo study was not performed, results of the in vitro experiments were deemed sufficient to show acceleration of drug release from the extended release capsules. In another study with extended release tablets of oxymorphone hydrochloride (Opana ER®), in vitro experiments did not show rapid drug release in 500 mL of 0.1 N HCl containing either 4, 20 or 40% ethanol (Opana ER Package Insert, Endo Pharmaceuticals Inc., Chadds Ford, PA). However, the in vivo study indicated that mean AUC was 13% higher, though not statistically significant, when a single dose of Opana ER® (40 mg) was co-administered with 240 mL of 40% alcohol. No change in AUC was observed at the other concentrations of alcohol administered in the in vivo study (0, 4 and 20%) . Based on these findings with Avinza® and Opana ER®, their product labels contain black-box warnings to state that co-administration of alcohol with the drug may result in a potentially fatal overdose of the drug.
Regulatory considerations
A memorandum from Ajaz S. Hussain, Ph. D. (who was then Deputy Director, Office of Pharmaceutical Science, CDER, FDA), to members of the Advisory Committee for Pharmaceutical Science (ACPS) was issued on Sept 27, 2005 (FDA 2005b . The purpose of the memo was to set the stage for a 2-day meeting in the following month to discuss some important scientific topics. Two presentations were planned to make the committee aware of a then new concern called "alcohol induced dose dumping" which was defined as the rapid drug release of the entire amount (or significant fraction) of the drug contained in a modified release dosage form due to concomitant consumption with alcohol. Dramatic increases in the release rate of a formulation can pose a significant safety risk to patients. Dose dumping can also affect the efficacy of certain medications. Both of these risks depend on the therapeutic indication and the therapeutic index of a drug.
US FDA's position
Although FDA has issued a formal guidance that covers dose dumping resulting from the effects of food consumption, only a draft guidance has been issued for alcohol induced dose dumping (AIDD) (CDER/FDA 2002; CDER/FDA 2014) . We can infer a position from a collective summary of presentations from and comments made by FDA members. Inferred guidance suggests that a quality-by-design approach should be used to develop formulations that are robust with respect to concomitant consumption of alcohol. The test should involve the use of 0.1 N HCl media with differing amounts of ethanol (v/v) added to give the following percentages of ethanol in the media: 0, 5, 20, and 40%. In addition to the fasted media (typically 0.1 N hydrochloric acid), the agency wants to see AIDD in the medium that is validated for release and stability testing of the drug product.
This appears to be a very conservative position, as one of the in vitro conditions (40% alcohol) suggests a reallife situation where one would consume the formulated product with a glass of alcohol equivalent to 80-proof whiskey. It is believed (and it was stated off record) that the Agency's current thinking is that if in vitro testing shows little effect of alcohol throughout this range, then the risk of in vivo dose dumping would be low.
The FDA's Division of Bioequivalence (DBE) now expects information on in vitro dose dumping in the presence of alcohol in its review of ANDAs for certain classes of MR drug products such as opiods (FDA 2005a) . This is in response to known safety concerns associated with AIDD that can occur with some MR products. The DBE expects ANDA applicants for MR generics to perform in vitro tests to characterize dose dumping in alcohol if such tests were requested by the Agency for the initial new drug application. More details can be found in FDA's Guidance for Industry, Individual Products Bioequivalence Recommendations Guidances (Anand et al. 2011) .
Health Canada's position
Health Canada's Therapeutic Products Directorate (TPD), the Canadian federal authority that regulates pharmaceutical drugs and medical devices for human use issued a similar warning concerning the potentially deadly interaction between one particular slow-release "opioid" painkiller, Palladone XL™, and alcohol in any amount.
The FDA asked Purdue Pharma L.P., to withdraw the drug product from the market in the US. At the same time, the FDA issued a series of alerts about this specific drug product. Canada's TPD took a different approach by extending its warning to all opioids because of similar potential dangers. In 2012, the FDA issued a guidance to prescriber educators to caution patients that the use of CNS depressants, alcohol, or illegal drugs with MR or long-acting opioid analgesics can cause overdose and death.
Both agencies agree on the need for in vitro tests to determine if alcohol impairs the performance of MR dosage forms containing APIs that could present patient risks. In vitro tests could obviate the need for or at least reduce the number of patients who might be put at risk in potentially dangerous clinical studies.
Most, if not all other regulatory agencies throughout the world defer to the FDA's position on this subject.
EU position
General guidance from the European Medicines Agency (EMA) states that dissolution tests must be developed and validated for all modified-release formulations. The tests must be capable of:
(1) Discriminating between batches with respect to critical manufacturing variables that may have an impact on the desired bioavailability (2) Showing batch to batch consistency of pivotal clinical, bioavailability, and routine production batches (3) Determining stability of the relevant release characteristics of the product ((1999) The concern of the effects of co-consumption of alcohol adds a fourth element in that modified-release formulations must be shown to be robust with respect to the presence of alcohol. Testing for AIDD is performed using the same dissolution medium and apparatus as the validated dissolution method with 0, 5, 10 and 20% ethanol. If AIDD is observed or suspected, reformulation of the product should be considered ((2014) Guideline on the pharmacokinetic and clinical evaluation of modified release dosage forms (EMA/ CPMP/EWP/280/96 Corr1). in, Committee for Medicinal Products for Human Use (CHMP); EMA, Quality of medicines questions and answers: Part 2, Subchapter: Specific types of product-Need for in-vitro dissolution studies with alcohol for modified release oral products including opioid drug products, in, http://www.ema.-europa.eu/ema/index.jsp?curl=pages/regulation/q_and_a/ q_and_a_detail_000072.jsp#section10). The lack of the 40% ethanol is an indication of a lack of harmonization between the EMA and the FDA.
The EMA reviewed and provided comments on modified-release pharmaceutical products intended for pain management. Most of these products contain an opioid as the active pharmaceutical ingredient. The EMA stated that "most of these medicines continue to outweigh their risks" and that controlling the release rate within a formulation makes pain management more effective ((1999) Note for guidance on quality of modified release products: a oral dosage forms, B: transdermal dosage forms section 1 (Quality), in, European Medicines Agency Committee for Proprietary Medicinal Products). The EMA specifically stated that due to safety concerns, controlled-release products containing polymethacrylatetriethylcitrate(polymer-plasticizer combination) should be removed from the market and reformulated to make them more robust with respect to alcohol. The EMA also stated that warnings on the interactions of these drugs with alcohol should be made consistent across the class ((1999) Note for guidance on quality of modified release products: a oral dosage forms, B: transdermal dosage forms section 1 (Quality), in, European Medicines Agency Committee for Proprietary Medicinal Products; (2010) European Medicines Agency concludes review of modified-release oral opioids of the WHO level III scale for the management of pain (Press Release)).
Factors that influence AIDD
Several factors play an important role in enhancing or diminishing the potential for AIDD including: dosage form properties, absorption and metabolism of ethanol, dilution of stomach fluids, and gastric emptying. While studies have discussed the differences in gastric emptying in the fed and fasted states (Higaki et al. 2008) , it is intuitive that delayed gastric emptying will increase the propensity of dose dumping, especially in ethanol vulnerable formulations. Indeed, concentrations of ethanol as low as 4 and 10% have demonstrated prolonged gastric emptying times (Franke et al. 2004 ). Additionally, consumption of alcohol will alter the amount of stomach fluids. Given that the volume of fluid under fasted conditions is significantly smaller than that under fed conditions (Schiller et al. 2005) , gastric dilution effects are expected to be minimal for the former. Dosage form properties also play a critical role in determining the vulnerability of a formulation to AIDD. Most oral MR dosage forms are tablets or capsules, formulated by incorporating the drug in a polymeric matrix. Depending on the polymer type (hydrophobic, hydrophilic or a combination thereof ), drug release from an MR type tablet will be governed by the rate of diffusion of liquid into the polymer and consequently, diffusion of drug out of the matrix. A similar strategy is also employed in MR type capsules where a polymer matrix coats an inert bead containing adsorbed drug. These factors should be considered prior to dosage form development and evaluation, whether in vitro or in vivo.
Clinical case studies
With growing interest in the area of dose dumping due to alcohol, the mid-2000's saw a few clinical studies demonstrate the ruggedness of opioid containing MR dosage forms to AIDD in vivo. In these open-label, single-dose, crossover studies in healthy volunteers, the pharmacokinetics of the opioid from a MR dosage form co-administered with 4% alcohol (approx. 8 oz of beer), 20% alcohol (mixed drinks), and 40% alcohol (neat liquor) under fed and fasted conditions, was assessed. Range 0.5-1.9 0.4-1.5 0.6-3.4
Hydromorphone extended release capsules
The effect of alcohol co-ingestion with Palladone XL™ was evaluated in an open-label, four-arm, cross over pharmacokinetic study under fasted (n = 24) and fed (n = 24) conditions in adult healthy subjects (FDA 2005a) . Prior to administration of the study drug, subjects were administered an opioid antagonist, naltrexone, to attenuate opioid-induced adverse events, after which they received 12 mg Palladone XL™ (hydromorphone hydrochloride) with 240 mL water containing 0% (control), 4, 20 or 40% alcohol in fed or fasted state. The data in Table 1 represent the ratio of C max values at 4, 20 and 40% alcohol when compared to the control (0% alcohol). The results of the study indicated that the effects of alcohol co-ingestion were more pronounced in the fasted state as compared to the fed state where the mean C max for Ratio 40 was 3.5 with a maximum value of 6. In comparison, the mean C max for Ratio 40 in the fasted state was 6 with a maximum value of 16 (Table 1) .
OROS push-pull containing hydromorphone
In another study, the effects of AIDD on hydromorphone hydrochloride formulated using OROS Push-Pull, a well known osmotically controlled release delivery system, was investigated in healthy subjects under fed and fasted conditions in an open-label, randomized, four-treatment, four-period, four-sequence, crossover study (Sathyan et al. 2008) . Subjects received 16 mg OROS hydromorphone with 240 mL orange juice or orange juice with 4, 20 or 40% alcohol in fed (Group 1) or fasted (Group 2) state. While T max and AUC inf values were similar for both groups (fed and fasted), higher C max values were observed with alcohol ingestion across the fed and fasted groups (Fig. 1 ). The authors attributed the higher C max values to the unusually high amount of alcohol (equivalent to 4-8 units of vodka) consumed within 20-30 min, a notably short duration and concluded that the changes in bioavailability of hydromorphone from the OROS technology were minimal.
Morphine sulfate extended release capsules
Alpharma Pharmaceuticals, the manufacturer of KADIAN (morphine sulfate extended release capsules)
carried out an open-label, single-dose, 3-way crossover pharmacokinetic study in healthy volunteers using 100 mg KADIAN co-administered with 40% alcohol in the fasted and fed conditions, and compared the results against 100 mg KADIAN administered with water (Johnson et al. 2008) . Additionally, the pharmacokinetics of an oral solution of 20 mg morphine sulfate (immediate release) with water, in the fasted state, was also investigated. As part of common practice in clinical studies with opioids, subjects were administered 50 mg naltrexone hydrochloride (tablet), an opioid antagonist, before and after treatment. From the study results (Fig. 2) , the authors concluded that the pharmacokinetics of morphine did not differ significantly between treatment groups and therefore, there was negligible in vivo interaction between KADIAN and alcohol. In another study on morphine sulfate formulated as EMBEDA extended release capsules (60 mg), bioavailability upon concomitant ingestion of alcohol in healthy subjects was examined under fasted conditions in an open-label, randomized, single-dose, 4-way crossover, 4-sequence drug interaction study. EMBEDA contains pellets of extended release morphine sulfate with sequestered naltrexone hydrochloride core (MS-sNT) and is indicated for the management of chronic, moderate to severe pain (Johnson et al. 2012) . The subjects in the study were administered 60 mg MS-sNT with 240 mL of 0, 4, 20 or 40% alcohol. The alcohol was administered in 60 mL quantities (shots) in 5 min intervals; with dosage form intake during the first shot. The pharmacokinetic data revealed no drug interaction between morphine in MS-sNT and 4 or 20% alcohol, i.e. no change in the rate of absorption or extent of exposure (Table 2) . Though overall bioavailability of morphine was not affected with co-ingestion of 40% alcohol (Ratio 40), there was a 2-fold increase in C max and reduction in T max from 9 to 4 h when compared with MS-sent administered with water. Naltrexone levels were unaffected by co-administration of alcohol.
Oxycodone controlled release capsules
The effects of alcohol on an abuse-resistant formulation of controlled release oxycodone (Remoxy 40 mg capsules) were investigated in a single-center, randomized, four-way crossover study (de Kater et al. 2008) . From the values in Table 3 , except for a slight drop in T max , co-ingestion of 4% alcohol had no effect on pharmacokinetic parameters. Though a slight decrease in C max was observed with 20% alcohol while administration of 40% alcohol caused a slight increase in pharmacokinetic parameters, the formulation maintained its controlled release properties.
Hydrocodone extended release capsules
The effect of alcohol on an oral, extended-release formulation of hydrocodone was evaluated in a threetreatment, three-period crossover study in healthy volunteers (Farr et al. 2015) . In the first period, 50 mg hydrocodone was administered with 240 mL of either 40% alcohol/orange juice, 20% alcohol/orange juice, or orange juice alone, after an overnight fast. Similar to other clinical studies with opioids, 50 mg naltrexone was administered approximately 12 h (with a light snack) and 2 h (fasted) prior to, and 10 h (with a light snack) after dosing of the study drug. Subjects received the alternative treatments according to a randomization code during the second and third treatment periods, with a 4-5 day separation between treatments. Similar exposures were obtained with 0 and 20% alcohol. With 40% alcohol, a shorter T max with higher C max and AUC values was observed (Fig. 3) . The authors concluded that while no dose dumping was seen, concomitant ingestion of alcohol with the hydrocodone extended release capsules was not advised. Two key points/lessons learned from the above clinical studies:
(a) Given the side-effects of ingesting 40% alcohol as multiple 'shots' immediately, the authors feel that a clinical study design should provide a reasonable time-frame for ingestion of alcohol. For instance, in their study with hydromorphone, subjects were advised to consume the orange juice-alcohol solutions slowly, but within 30 min, to avoid vomiting (Sathyan et al. 2008) . Such type of design may reduce study drop-out rates and thereby, associated costs and timelines. (b)To reduce adverse events before dosing the opioid drug, the authors agree with the sponsors' approach of administering naltrexone, an opioid receptor antagonist (Johnson et al. 2008; Farr et al. 2015) .
In vitro case studies
Multiple cases studies have been presented in the literature concerning AIDD. Retrospective studies have been conducted for AIDD where existing products on the market have been tested on their potential to dose dump in different levels of alcohol. Other studies have focused on formulation based comparisons where certain extended release excipients have been shown to be more vulnerable to dose dumping than others. A summary of some of these studies is presented. Opioids and other centrally acting drugs FDA ethanol study
The U.S. Food and Drug Administration published a paper that compared various oral modified-release products from different therapeutic areas (Smith et al. 2010 ).
The percentages of ethanol used in the studies were 5, 20 and 40% with the USP listed dissolution medium and methodology. The dissolution value (D A/N ) reported used the relative change in the amount of dissolution in the alcoholic medium compared to the values in the purely aqueous medium at a specific time point.
Where D A is the percent drug dissolved in alcoholic medium and D N is the percent drug dissolved in the "nonalcoholic" medium. These values were reported at 30 min and also plotted versus time through 8 h. Positive values indicate a greater release in alcohol and negative values indicate a slower release.
All capsules studied gave positive D A/N values for the 40% ethanol at 30 min whereas most tablets had negative values (Fig. 4) . Values over 900 were observed indicating >900% release compared to the non-alcohol medium. Most of the capsules were conventional beadsor pellet-filled hard gelatin capsules except for the opioid analgesics, which were made by melt extrusion technology or contained a mixture of immediate release and enteric-coated delayed release pellets. Those tablets that gave high D A/N values contain hypromellose (HPMC). 
Extended release opioids
Nine extended-release opioid products containing dihydrocodeine, morphine, oxycodone, hydromorphone, and tramadol were tested for AIDD over 2 h (Walden et al. 2007 ). The 2-h period is expected to be representative of the most extreme conditions likely to be encountered in vivo. Three to four time points were sampled for the first hour followed by the 2-h time point. Five of the products were tested at 5, 10, 15, 20, 25, 30, 35 and 40% ethanol while the other four products were tested at 4, 16, 24, 32 and 40% ethanol.
The results for most of the products indicated a negligible effect of ethanol on the release. One product, Palladone SR capsule, which utilizes a coated bead technology demonstrates a slower release at low levels of alcohol (5-15%) and a higher release at high levels of alcohol (35-40%) when compared to the control (0%) release rate (Figs. 5, 6 and 7) . D A/N values greater than 100 are considered to be a significant increase in drug release.
Perhaps the most interest aspect of this paper is the discussion about in vivo alcohol exposures. A strong case is made that in-vitro studies should be for a maximum time of 2 h to mimic in vivo physiology. Six in vivo studies were cited supporting this statement that discuss fasted and fed gastric emptying, alcohol absorption and alcohol metabolism as well as dilution effects by gastric fluids and saliva. This prompts questions as to whether clinical study designs reflect real life scenarios.
Codeine hot melt extruded pellets
Various formulations were investigated using hot-melt extruded pellets containing codeine phosphate (lower solubility in ethanol) and paracetamol (highly soluble in ethanol, see Paractemol hot melt extruded pellets section) were examined for resistance to alcohol dose dumping (Jedinger et al. 2015) . The formulations contained calcium stearate as matrix carrier and two ethanol-and water-insoluble solid lipids, glycerol distearate and glycerol dibehenate. Characterization of the powder substances and pellets were performed including DSC, FT-IR spectroscopy, solubility, media uptake, contact angle and pellet morphology. Dissolution results were presented in 0% ethanol in 0.1 N HCl, 20% ethanol in 0.1 N HCl and 40% ethanol in 0.1 N HCl. There were three formulations prepared that all contained 20% active ingredient. These formulations are:
(1) 70% CaSt with 10% glycerol distearate (Precirol), (2) 70% CaSt with 10% glycerol dibehenate (Compritol), and (3) 80% Calcium Stearate (CaSt),
The dissolution results of the codeine phosphate in 0% ethanol in 0.1 N HCl and 40% ethanol in 0.1 N HCl are presented in Fig. 8 . Codeine phosphate has a greater release after 2 h in 0.1 N HCl. The formulation with CaSt only has the highest release in 0.1 N HCl and only a slight increase in 40% ethanol. 
Three tramadol formulations evaluated
Three commercially available formulations of tramadol were evaluated for AIDD using full dissolution profiles at 0, 20 and 40% ethanol using the same dissolution method (Traynor et al. 2008 ). The three formulations had three various sensitivities to alcohol that depended on their excipient's solubility in alcohol (Table 4) . The main excipient in T-long® capsules, Eudragit® NE30D, is soluble in ethanol and showed AIDD in both 20 and 40% ethanol dissolution media. The two main excipients in Ultram® ER Tablet, povidone and ethylcellulose, are also soluble in alcohol. This formulation has an increased release profile in 40% alcohol medium when compared to the control (0% alcohol) medium. Lastly, the Tridural® Tablet contains Kollidon SR. This excipient is a physical mixture of polyvinylacetate (80%) that is insoluble in ethanol, and povidone (20%), that is soluble in alcohol.
The product shows a decrease in release rate in both 20 and 40% ethanol media ( Fig. 9 ) (Traynor et al. 2008 ).
Effect of ethanol on morphine sulfate SR
Dissolution AIDD studies were performed on Oramorph SR, 15, 30, 60 and 100 mg strengths at 4, 10, 20 and 40% ethanol concentration (Barkin et al. 2009 ). The dissolution for this product involves a two stage process where the product is run with 500 mL 0.1 N HCl dissolution media for 1 h in USP Apparatus I. The basket is removed and transferred to the second stage media, pH 7.5 phosphate buffer and run for 12 h (Fig. 10) . Results of the testing show similar release rates in the 4% alcohol media compared to the control without alcohol for the two lower strengths, 15 and 30 mg. The two higher strengths have slower release rates as the percentage of alcohol increases. These results indicate that this product is not vulnerable to dose dumping in ethanol.
Other (Non-Opioid) drugs Hydro-alcoholic media and the excipient polyacrylic acid polymer (Carbopol 71G) This paper looks at the effect of various levels of alcohol (0, 10, 20, 30, 40 and 50%) on tablet swelling and release of the drug hydrochlorothiazide (HCTZ) from a 50-50 mixture of carbopol 71G extended release matrix (Emeje et al. 2008) . Except for 30% ethanol media, all ethanolic media show a decrease in HCTZ release over 6 h when compared to the control (0%) media. HCTZ has an increased solubility with higher percentage of ethanol. Therefore, the decreased release rate in alcohol is caused by the polymer-alcohol interactions than the drug solubility in the dissolution medium (Figs. 11, 12 and 13) .
Hydro-alcoholic media and the ethanol resistant excipient polyacrylic acid polymer (Carbopol971G)
The effect of 0, 20 and 40% alcohol on the dissolution of caffeine, metformin hydrochloride and guaifenesin tablets formulated using Carbopol 971G polymer was studied. When compared to 0.1 N HCl (0% ethanol), low solubility of caffeine and metformin hydrochloride in ethanol led to slower release from dissolution media containing 20 or 40% v/v alcoholic media. For guaifenesin, slight slowing of drug release was noted with 10% (but not 20%) Carbopol 971G polymer ( Fig. 14) ( (2011) 
Four ethanol exposure scenarios for mesalazine ER
Three mesalazine extended release products were tested under four different concentrations and durations of alcohol and pH medium (Fadda et al. 2008) . Two of the mesalazine products studied are enteric coated and designed to release in the distal end of the GI tract while the third product was more of a traditional extended-release product using ethyl cellulose. This paper considers the pattern of alcohol distribution in the GI tract and how they vary under different physiological states. The products were exposed to a pH transition to simulate different regions of the GI tract. The tablets were transferred from one medium to another. The percentages of alcohol studied were 0 (control), 5, 20, 30 and 40%. The data for the 5% alcohol was not presented as it was similar to the control. The four scenarios lasting a total of 10 h were:
(1) 0.1 N HCl with ethanol for 2 h followed by pH 6.8 phosphate for 2 h then pH 7.4 phosphate (2) 0.1 N HCl with ethanol for 30 min followed by 0.1 N HCl with no ethanol for 90 min followed by pH 6.8 phosphate for 2 h then pH 7.4 phosphate (3) 0.1 N HCl with ethanol for 30 min followed by pH 6.8 phosphate for 2 h then pH 7.4 phosphate (4)0.1 N HCl with ethanol for 30 min followed by pH 6.8 phosphate for 2 h (first 15 min containing ethanol equivalent to half the concentration in acid) followed by pH 7.4 phosphate Alcohol was observed to have a significant impact on the release profile of all three products. For the enteric coated products, exposure to alcohol during the acid stage caused the coating integrity to be compromised and the drug to release earlier than designed. The four scenarios did show different sensitivities to alcohol. The ethylcellulose product had a significant increase in the early stage of dissolution for both the 30 and 40% alcohol when compared to the control (Figs. 15 and 16 ).
Ethanol resistant polymeric films containing theophylline
Dissolution AIDD studies were performed on extended release theophylline formulations contains ethylcellulose and very low, low, medium and high viscosity guar gums at 0, and 40% ethanol concentrations (Rosiaux et al. 2013) . The dissolution for this product involves a two stage process where the product is run with 900 mL 0.1 N HCl dissolution media for 2 h in USP Apparatus II. Complete media change occurred to the second stage media, pH 7.4 phosphate buffer and run for 6 h more (Fig. 17) .
The formulation process coated theophylline matrix cores using a fluidized bed coater with different ethylcellulose:guar gum blends. Additional formulation experiments were performed on film properties, addition of anti-tacking agents, curing and stability studies.
Results of the dissolution testing show similar release rates in the 40% alcohol media compared to the control without alcohol for the medium and high viscosity guar gum coatings. The two lower viscosity guar gum coating have accelerated release rates in the 40% alcohol medium. These results indicate that the higher viscosity process is not vulnerable to dose dumping in ethanol.
Hydro-alcoholic media and hypromellose (HPMC) matrix systems
The influence of hydro-alcoholic media on HPMC matrix formulations of three different drugs (felodipine, gliclazide and metformin) that vary in aqueous and alcohol solubility was investigated by Colorcon (Levina et al. 2007, Table 5) . Dissolution profiles over 12 h were performed at 0, 5 and 40% ethanol media at multiple time points (26 per profile). Two durations of alcohol exposure were performed for 1 h and for the entire 12 h. The 1 h exposure was considered to be a more realistic model to exposures that would occur in vivo.
The 12-h alcohol exposure showed no significant change is drug release profiles for two of the three drugs. The metformin formulation did have a decrease in drug release profile at 40% ethanol medium that was caused by the decrease in solubility of metformin in alcohol.
The 1 h ethanol exposures followed by 11 h is the standard dissolution media did not show significant change in drug release profiles for all three drug at both 5 and 40% ethanol media (Figs. 18, 19, 20, 21, 22 and 23) . 
Effect of ethanol on aspirin in hypromellose matrices
This paper looks the impact of various percentages of alcohol on dissolution and a variety of physicochemical properties of aspirin in a hypromellose (HPMC) matrix (Roberts et al. 2007) . Dissolution profiles were performed on 0, 10, 20, 30 and 40% ethanol in an acetate buffer media. Additional alcohol experiments included aspirin solubility, aspirin-HPMC compacting swelling, HPMC viscosity and cloud point. Dissolution profiles through 6 h indicate that there is an increase in drug release with an increase in alcohol concentration, but the profiles do not show dose dumping. The experiments indicate that both an increase in aspirin solubility and reduction in matrix swelling at higher alcohol concentrations play competing roles in release of drug from the HPMC matrix in alcoholic media (Figs. 24 and 25) .
Effect of alcohol on drug release kinetics from hpmc-based matrix tablets using model drugs Six tablet formulations with HPMC were studied using diclofenac potassium, tramadol HCl and venlafaxine HCl. The six formulations were tested with pH 6.8 phosphate buffer using USP Apparatus 2 at 50 rpm with media containing 0, 10, 20, 30, and 40% ethanol. In all cases, drug release increased with an increase in alcohol content in the dissolution medium. Drug release was faster for those formulations that had lactose as a filler as Fig. 24 Effect of ethanol on solubility of aspirin and its release exponent from hypromellose matrices (data from reference (Roberts et al. 2007)) opposed to microcrystalline cellulose. All formulations failed f 2 in the presence of dissolution medium containing 40% ethanol when compared to 0% ethanol medium (Table 6 ). Swelling studies demonstrate that swelling decreases with higher alcohol content in the dissolution medium (Figs. 26 and 27) (Avachat & Nandare 2014) .
Ethanol effects on verapamil Meltrex
Dissolution AIDD studies were performed on four commercially available extended release formulations of verapamil 240 mg strength at 5, 10, 20 and 40% ethanol concentration (Roth et al. 2009 ). The dissolution for this product uses 900 mL of pH 6.8 phosphate buffer dissolution media in USP Apparatus II and run for 8-10 h. Results of the testing show similar release rates in the 4 alcohol media compared to the control without alcohol for verapamil Meltrex formulation. Verapamil Meltrex uses an innovative melt extrusion process to manufacture the tablets. The three other formulations have significantly accelerated release rates at the 20 and 40% alcohol levels. These results indicate that verapamil is not vulnerable to dose dumping in ethanol, whereas the other three formulations have significant AIDD at high alcohol concentrations (Fig. 28) .
Polyethylene oxide extended-release matrix tablets
Two tablet formulations with polyethylene oxide (PEO) were studied using Gliciazide and metformin. The two tablet formulations were tested with 5 and 40% ethanol in water for 12 h and with exposure to the same alcohol solutions for 1 h followed by dissolution with water ( Fig. 29) (Palmer et al. 2011) . The f 2 similarity results indicate that the dissolution profiles were not impacted by ethanol exposure in all conditions except the metformin in 40% ethanol for 12 h. In this case, the release profile was reduced indicating a resistance to alcohol dose dumping. Tablet swelling was slightly reduced in ethanol. These formulations were resistant to alcohol dose dumping.
Paractemol hot melt extruded pellets
In a manner similar to that described with codeine hot melt extruded pellets (Codeine hot melt extruded pellets section), the dissolution results of the paracetamol in 0% ethanol in 0.1 N HCl and 20% ethanol in 0.1 N HCl were similar, so the 20% data has not been presented (Fig. 30) (Jedinger et al. 2015) . Paracetamol does not have significant release after 2 h in 0.1 N HCl while in medium with 40% ethanol, dose dumping is observed. The formulation containing Precirol has the largest dose released after 2 h. As in the study with codeine, the formulation containing Precirol has the largest dose released after 2 h. Fig. 31 Effect of alcohol on release Naproxen EC, Ecotrin®, and Asacol® tablets (delayed release), and prolonged release dosage forms, namely, Nifedipine ER tablets, Propranolol ER, venlafaxine XR, and Pentasa® capsules (dotted line indicates a change from SGF with or without ethanol, to SIF) (data from reference (Talukder et al. 2009)) Evaluation of the effects of ethanol on dissolution of various types of modified release dosage forms
Delayed release products, such as, Naproxen EC, Ecotrin®, and Asacol® tablets, and prolonged release dosage forms, namely, Nifedipine ER tablets, Propranolol ER, Venlafaxine XR, and Pentasa® capsules were obtained from a local drug store. In-vitro evaluations of release characteristics of the dosage forms were conducted in 900 ml of USP simulated gastric fluid without the enzymes (SGF) for 2 h, followed by dissolution in simulated intestinal fluid without the enzymes (SIF) in a VanKel USP apparatus I at 50 rpm using on-line UV spectrophotometric detection. To evaluate the effect of alcohol, the dissolutions were carried out in SGF with different levels of ethyl alcohol (5, 10, and 20% v/v) for 2 h followed by dissolution in SIF for 10 h (Fig. 31 ) (Talukder et al. 2009 ).
Conclusions
A comprehensive review has been presented of in vivo and in vitro studies that have investigated alcohol induced dose dumping (AIDD) in modified release dosage forms. The regulatory perspective of the FDA, EU and Canadian regulatory authorities has been reviewed. Some clinical case studies were discussed from some opioid extended-release PK studies. Lastly, a review of in vitro dissolution studies has been presented that demonstrate the impact of formulation excipients of modified release dose forms on release of drug with exposure to various levels of ethanol. The formulations in the case studies had a range of sensitivity to alcohol induced dose dumping. Based on information from regulatory authorities, those MR formulations that show significant AIDD may need to be reformulated. Alternately, less severe cases may require a clinical PK study to determine the extent of the impact of alcohol on the release of the drug. 
